These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 594790)

  • 21. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
    Soloway MS
    Am J Clin Oncol; 1988; 11 Suppl 1():S29-32. PubMed ID: 3133944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of estrogen therapy on metastatic carcinoma of the prostate.
    Anikwe RM
    Int Surg; 1977 Oct; 62(10):532-6. PubMed ID: 591215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy--5-year follow-up.
    Giuliani L; Pescatore D; Giberti C; Martorana G; Natta G
    Eur Urol; 1980; 6(3):145-8. PubMed ID: 7371659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate.
    Huben RP; Murphy GP
    Cancer; 1988 Nov; 62(9):1881-7. PubMed ID: 3139279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bilateral orchiectomy for carcinoma of prostate. Response of serum testosterone and clinical response to subsequent estrogen therapy.
    Klugo RC; Farah RN; Cerny JC
    Urology; 1981 Jan; 17(1):49-50. PubMed ID: 7456197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Castration in the treatment of locally advanced or metastatic prostate cancer].
    Mongiat-Artus P
    Rev Prat; 2013 Apr; 63(4):509-10. PubMed ID: 23682480
    [No Abstract]   [Full Text] [Related]  

  • 27. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer.
    Lin BJ; Chen KK; Chen MT; Chang LS
    Urology; 1994 Jun; 43(6):834-7. PubMed ID: 8197647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review.
    Blackard CE
    Cancer Chemother Rep; 1975; 59(1):225-7. PubMed ID: 1093670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recurrence of cancer of the prostate after initial treatment with diethylstilbestrol (DES) in a homogeneous series of 175 cases].
    Reziciner S
    Ann Urol (Paris); 1997; 31(4):213-24. PubMed ID: 9412346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients.
    Klioze SS; Miller MF; Spiro TP
    Am J Clin Oncol; 1988; 11 Suppl 2():S176-82. PubMed ID: 3149455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of metastatic prostate cancer. Factors that influence treatment selection and methods to increase acceptance of orchiectomy.
    Merrill DC
    Urology; 1988 Nov; 32(5):408-12. PubMed ID: 3188303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Initial experience with ethinyl estradiol sulfonate (J 96) in the therapy of prostate carcinoma].
    Guddat HM; Schnorr D; Dörner G; Stahl F; Rohde W
    Z Urol Nephrol; 1979 Mar; 72(3):153-7. PubMed ID: 380227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orchiectomy for advanced prostatic carcinoma. A reevaluation.
    Blackard CE; Byar DP; Jordan WP
    Urology; 1973 Jun; 1(6):553-60. PubMed ID: 4588820
    [No Abstract]   [Full Text] [Related]  

  • 34. Primary orchiectomy versus estrogen therapy in advanced prostatic cancer--a randomized study: results after 7 to 10 years of followup.
    Johansson JE; Andersson SO; Holmberg L; Bergström R
    J Urol; 1991 Mar; 145(3):519-22; discussion 522-3. PubMed ID: 1997702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study.
    Zagars GK; Johnson DE; von Eschenbach AC; Hussey DH
    Int J Radiat Oncol Biol Phys; 1988 Jun; 14(6):1085-91. PubMed ID: 3133327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carcinoma of prostate. Increased mortality and cardio-vascular complications associated with oestrogen therapy as compared with orchiectomy.
    Gardner AM; Setakis N
    Bristol Med Chir J; 1983 Jul; 98(367):117-9. PubMed ID: 6616292
    [No Abstract]   [Full Text] [Related]  

  • 37. Endocrine treatment of prostatic cancer.
    Pollen JJ
    Urology; 1983 Jun; 21(6):555-8. PubMed ID: 6868224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of platelet aggregation caused by estrogen treatment in patients with carcinoma of the prostate.
    Eisen M; Napp HE; Vock R
    J Urol; 1975 Jul; 114(1):93-7. PubMed ID: 1142508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early combined hormonal and chemotherapy for metastatic carcinoma of prostate.
    Mukamel E; Nissenkorn I; Servadio C
    Urology; 1980 Sep; 16(3):257-60. PubMed ID: 7423702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Orchiectomy and delayed radiotherapy as treatment for prostatic carcinoma. A 10-year survey.
    Meffan PM; Nacey JN
    Br J Urol; 1986 Aug; 58(4):417-22. PubMed ID: 3756411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.